Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of RA receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/CVeAV0ZXA8 https://t.co/A8McLt0rSl

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recos on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/OaRBNfhNCJ https://t.co/gF9QFDYTsu

Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn

Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC

Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy

Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L

Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw

Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1

HRT for RA? Not Yet Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi

Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU